Table 1.

Clinical characteristics of subjects

GroupCohort 1 (n = 19)Cohort 2 (n = 22)p-value
Disease duration (y)4.9 (2.8)4.3 (2.1)0.4
H&Y2 (1.5–3)2 (1–3)0.9
FAB16.9 (0.8)17.0 (1.3)0.8
UPDRS
    Total28.5 (8.7)29.4 (6.2)0.7
    Nontremor (B + R)
        Most affected10.4 (1.8)10.7 (3.5)0.7
        Least affected4.6 (3.7)4.7 (2.3)0.8
    Axial7.6 (3.5)6.3 (2.3)0.3
Rest tremor
    TRSa
        Most affected3.6 (1.4)3.0 (1.2)0.2
        Least affected0.5 (1.0)0.8 (1.3)0.4
    UPDRS
        Most affected3.5 (1.2)3.0 (1.2)0.6
        Least affected0.5 (1.1)0.8 (1.3)0.5

  • Disease characteristics of tremor-dominant patients of Cohort 1 and 2 are shown [Hoehn & Yahr (H&Y): median, minimum, and maximum scores in parentheses; other parameters: mean, SD in parentheses] and compared between groups (Kruskal–Wallis for H&Y scales and for the least affected parts, otherwise 2-tailed and 2-samples t test). Disease severity of each patient was measured using the H&Y stages (maximum = 5) stages and the UPDRS part III (UPDRS; maximum score is 108). B + R, Limb bradykinesia and rigidity (sum of UPDRS items 22–26). Axial, Axial symptoms (sum of UPDRS items 18, 19, 22, and 27–31). The Frontal Assessment Battery (FAB) was used as a measure of cognitive function (Dubois et al., 2000; maximum = 18). Duration was defined as the time since subjective symptom onset (in years). Patients' resting tremor severity was scored using Part A of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) (Stacy et al., 2007; maximum = 8 points for each side) and item 20 of the UPDRS. Affected side did not differ between the two Cohorts (p > 0.2).

  • ↵aEight patients who did not receive a TRS test (Cohort 2) were left out.